234 related articles for article (PubMed ID: 31470645)
21. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design.
Ma C; Wang L; Tao X; Zhang N; Yang Y; Tseng CK; Li F; Zhou Y; Jiang S; Du L
Vaccine; 2014 Oct; 32(46):6170-6176. PubMed ID: 25240756
[TBL] [Abstract][Full Text] [Related]
22. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection.
Tai W; Zhao G; Sun S; Guo Y; Wang Y; Tao X; Tseng CK; Li F; Jiang S; Du L; Zhou Y
Virology; 2016 Dec; 499():375-382. PubMed ID: 27750111
[TBL] [Abstract][Full Text] [Related]
23. Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape.
Wang L; Shi W; Chappell JD; Joyce MG; Zhang Y; Kanekiyo M; Becker MM; van Doremalen N; Fischer R; Wang N; Corbett KS; Choe M; Mason RD; Van Galen JG; Zhou T; Saunders KO; Tatti KM; Haynes LM; Kwong PD; Modjarrad K; Kong WP; McLellan JS; Denison MR; Munster VJ; Mascola JR; Graham BS
J Virol; 2018 May; 92(10):. PubMed ID: 29514901
[TBL] [Abstract][Full Text] [Related]
24. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus.
Guo X; Deng Y; Chen H; Lan J; Wang W; Zou X; Hung T; Lu Z; Tan W
Immunology; 2015 Aug; 145(4):476-84. PubMed ID: 25762305
[TBL] [Abstract][Full Text] [Related]
25. Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus.
Deng Y; Lan J; Bao L; Huang B; Ye F; Chen Y; Yao Y; Wang W; Qin C; Tan W
Emerg Microbes Infect; 2018 Apr; 7(1):60. PubMed ID: 29618723
[TBL] [Abstract][Full Text] [Related]
26. DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice.
Chi H; Zheng X; Wang X; Wang C; Wang H; Gai W; Perlman S; Yang S; Zhao J; Xia X
Vaccine; 2017 Apr; 35(16):2069-2075. PubMed ID: 28314561
[TBL] [Abstract][Full Text] [Related]
27. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.
Alharbi NK; Padron-Regalado E; Thompson CP; Kupke A; Wells D; Sloan MA; Grehan K; Temperton N; Lambe T; Warimwe G; Becker S; Hill AVS; Gilbert SC
Vaccine; 2017 Jun; 35(30):3780-3788. PubMed ID: 28579232
[TBL] [Abstract][Full Text] [Related]
28. A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.
Malczyk AH; Kupke A; Prüfer S; Scheuplein VA; Hutzler S; Kreuz D; Beissert T; Bauer S; Hubich-Rau S; Tondera C; Eldin HS; Schmidt J; Vergara-Alert J; Süzer Y; Seifried J; Hanschmann KM; Kalinke U; Herold S; Sahin U; Cichutek K; Waibler Z; Eickmann M; Becker S; Mühlebach MD
J Virol; 2015 Nov; 89(22):11654-67. PubMed ID: 26355094
[TBL] [Abstract][Full Text] [Related]
29. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.
Zhang N; Channappanavar R; Ma C; Wang L; Tang J; Garron T; Tao X; Tasneem S; Lu L; Tseng CT; Zhou Y; Perlman S; Jiang S; Du L
Cell Mol Immunol; 2016 Mar; 13(2):180-90. PubMed ID: 25640653
[TBL] [Abstract][Full Text] [Related]
30. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
[TBL] [Abstract][Full Text] [Related]
31. Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection.
Li K; Li Z; Wohlford-Lenane C; Meyerholz DK; Channappanavar R; An D; Perlman S; McCray PB; He B
mBio; 2020 Apr; 11(2):. PubMed ID: 32265331
[TBL] [Abstract][Full Text] [Related]
32. Current advancements and potential strategies in the development of MERS-CoV vaccines.
Zhang N; Jiang S; Du L
Expert Rev Vaccines; 2014 Jun; 13(6):761-74. PubMed ID: 24766432
[TBL] [Abstract][Full Text] [Related]
33. Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model.
Bodmer BS; Fiedler AH; Hanauer JRH; Prüfer S; Mühlebach MD
Virology; 2018 Aug; 521():99-107. PubMed ID: 29902727
[TBL] [Abstract][Full Text] [Related]
34. Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.
Wang Y; Tai W; Yang J; Zhao G; Sun S; Tseng CK; Jiang S; Zhou Y; Du L; Gao J
Hum Vaccin Immunother; 2017 Jul; 13(7):1615-1624. PubMed ID: 28277821
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein.
Al-Amri SS; Abbas AT; Siddiq LA; Alghamdi A; Sanki MA; Al-Muhanna MK; Alhabbab RY; Azhar EI; Li X; Hashem AM
Sci Rep; 2017 Mar; 7():44875. PubMed ID: 28332568
[TBL] [Abstract][Full Text] [Related]
36. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS
Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978
[TBL] [Abstract][Full Text] [Related]
37. MERS-CoV spike protein: Targets for vaccines and therapeutics.
Wang Q; Wong G; Lu G; Yan J; Gao GF
Antiviral Res; 2016 Sep; 133():165-77. PubMed ID: 27468951
[TBL] [Abstract][Full Text] [Related]
38. Characterization and immunogenicity assessment of MERS-CoV pre-fusion spike trimeric oligomers as vaccine immunogen.
Ahuja R; Vishwakarma P; Raj S; Kumar V; Khatri R; Lohiya B; Saxena S; Kaur G; Singh G; Asthana S; Ahmed S; Samal S
Hum Vaccin Immunother; 2024 Dec; 20(1):2351664. PubMed ID: 38757508
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of candidate vaccine approaches for MERS-CoV.
Wang L; Shi W; Joyce MG; Modjarrad K; Zhang Y; Leung K; Lees CR; Zhou T; Yassine HM; Kanekiyo M; Yang ZY; Chen X; Becker MM; Freeman M; Vogel L; Johnson JC; Olinger G; Todd JP; Bagci U; Solomon J; Mollura DJ; Hensley L; Jahrling P; Denison MR; Rao SS; Subbarao K; Kwong PD; Mascola JR; Kong WP; Graham BS
Nat Commun; 2015 Jul; 6():7712. PubMed ID: 26218507
[TBL] [Abstract][Full Text] [Related]
40. Antibodies and vaccines against Middle East respiratory syndrome coronavirus.
Xu J; Jia W; Wang P; Zhang S; Shi X; Wang X; Zhang L
Emerg Microbes Infect; 2019; 8(1):841-856. PubMed ID: 31169078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
